Tectonic Advisors LLC Acquires 6,438 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Tectonic Advisors LLC lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 26.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 30,559 shares of the biopharmaceutical company's stock after acquiring an additional 6,438 shares during the quarter. Tectonic Advisors LLC's holdings in Halozyme Therapeutics were worth $1,950,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Penserra Capital Management LLC bought a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $125,000. Bessemer Group Inc. raised its holdings in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after acquiring an additional 524,802 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Halozyme Therapeutics by 29.4% during the first quarter. Fifth Third Bancorp now owns 10,017 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 2,276 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Halozyme Therapeutics by 199.0% during the first quarter. GAMMA Investing LLC now owns 2,802 shares of the biopharmaceutical company's stock valued at $179,000 after acquiring an additional 1,865 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research reports. Leerink Partners downgraded Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective for the company. in a report on Tuesday, May 13th. Leerink Partnrs downgraded Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and issued a $72.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Finally, Benchmark downgraded Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $62.70.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total transaction of $1,128,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $41,403,763.17. The trade was a 2.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the transaction, the director owned 28,611 shares of the company's stock, valued at approximately $1,727,246.07. This trade represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 64,497 shares of company stock worth $3,533,884. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Down 0.3%

Shares of NASDAQ HALO traded down $0.20 during trading on Thursday, reaching $57.81. The company had a trading volume of 1,110,490 shares, compared to its average volume of 1,750,384. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $70.51. The stock has a market cap of $7.12 billion, a PE ratio of 15.38, a P/E/G ratio of 0.38 and a beta of 1.15. The business's 50-day moving average is $54.68 and its 200 day moving average is $57.08. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts' consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million for the quarter, compared to the consensus estimate of $231.21 million. During the same quarter in the prior year, the company earned $0.79 earnings per share. Halozyme Therapeutics's revenue was up 35.2% on a year-over-year basis. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.